Arosa cannot deny damaging, malicious wrongdoing carried out against DATATRAK throughout Activist campaign
CLEVELAND, December 31, 2015 /PRNewswire/ – DATATRAK International, Inc. (OTCQX: DTRK), the leader in developing cloud-based, unified dClinical™ technologies and delivering related services for the clinical trials industry, today called upon the shareholders to review the following information and reject Arosa's claims.
- Arosa has not refuted the direct evidence of misconduct that came with the subpoena of a Yahoo! user account.
- The smear campaign carried out by this misconduct, which included targeting customers and undoubtedly damaged customer relationships, has destroyed shareholder value.
- Due to the timing of this development, the Board of Directors postponed the Annual Meeting to allow adequate time for shareholders to react.
- The Company announced the Annual Meeting date of January 8, 2016, and fully intends, whatever the results, to uphold the shareholders now informed votes without further delay.
Jerome Kaiser, Lead Independent Director, commented, "The Board of Directors felt it was important for DATATRAK shareholders to review the new information before the Annual Meeting was held. We believe this information is direct evidence that Arosa is tied to the damaging campaign that targeted the Company. With that said, we fully intend to uphold the result of the January 8 Annual Meeting after shareholders have had the opportunity to understand and assess." Kaiser continued, "The Board of Directors looks forward to the results of the election and focusing on the future of the business."
If you have any questions or need assistance in voting your WHITE PROXY CARD, please contact Morrow & Co., our proxy solicitor, toll-free at 800-662-5200, or via E-mail at [email protected]
DATATRAK is a worldwide technology and consulting Company delivering digital clinical solutions and related services for the clinical trials industry. The Company delivers a portfolio of software solutions through the unified dClinical™ platform, safely accelerating clinical research, from Concept to Cure®.
DATATRAK International is a worldwide technology and services Company delivering Unified dClinical™ solutions and related services for the clinical trials industry. DATATRAK built its multi-component, comprehensive solution on a single, unified platform and expanded this concept to include services delivery via DATATRAK's Clinical and Consulting Services group. The Company delivers a complete portfolio of software products designed to accelerate the reporting of clinical research data from sites to sponsors and ultimately regulatory authorities, faster and more efficiently than loosely integrated technologies. The DATATRAK ONE® software solution, deployed worldwide through an ASP or Enterprise Transfer offering, supports Phase I – Phase IV drug and device studies in multiple languages throughout the world. DATATRAK has offices located in Chicago, IL; Cary Research Triangle Park (RTP), North Carolina; Bryan, Texas; and Cleveland, Ohio. For more information, visit http://www.datatrak.com.
Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management's expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors which are difficult to predict and, in many instances, are beyond the control of the Company, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. For a list of certain factors that may cause actual results to differ materially from those contemplated in these forward looking statements, please see the Company's report filed with the OTCQX Market on March 13, 2015 announcing its results for the full year period ended December 31, 2014. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.
Investor Relations Contact: Chris Hodges or Nick Hughes, Alpha IR Group, [email protected]